JP2003503319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003503319A5 JP2003503319A5 JP2001505684A JP2001505684A JP2003503319A5 JP 2003503319 A5 JP2003503319 A5 JP 2003503319A5 JP 2001505684 A JP2001505684 A JP 2001505684A JP 2001505684 A JP2001505684 A JP 2001505684A JP 2003503319 A5 JP2003503319 A5 JP 2003503319A5
- Authority
- JP
- Japan
- Prior art keywords
- ucp
- membrane
- inhibitor
- lysosomal
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 description 44
- 239000003112 inhibitor Substances 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 210000000170 cell membrane Anatomy 0.000 description 19
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 17
- 229940012843 omega-3 fatty acid Drugs 0.000 description 16
- 239000006014 omega-3 oil Substances 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000002132 lysosomal effect Effects 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 10
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000001246 colloidal dispersion Methods 0.000 description 6
- 239000012190 activator Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14057499P | 1999-06-23 | 1999-06-23 | |
| US60/140,574 | 1999-06-23 | ||
| PCT/US2000/017245 WO2000078941A2 (en) | 1999-06-23 | 2000-06-22 | Methods and products for manipulating uncoupling protein expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003503319A JP2003503319A (ja) | 2003-01-28 |
| JP2003503319A5 true JP2003503319A5 (https=) | 2007-08-09 |
Family
ID=22491870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001505684A Pending JP2003503319A (ja) | 1999-06-23 | 2000-06-22 | アンカップリングタンパク質発現を操作する方法および産物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7816319B2 (https=) |
| EP (1) | EP1194168B1 (https=) |
| JP (1) | JP2003503319A (https=) |
| AT (1) | ATE462447T1 (https=) |
| AU (1) | AU780815B2 (https=) |
| CA (1) | CA2375508A1 (https=) |
| DE (1) | DE60044087D1 (https=) |
| HK (1) | HK1047032A1 (https=) |
| WO (1) | WO2000078941A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381413B1 (en) | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
| ATE462447T1 (de) | 1999-06-23 | 2010-04-15 | Univ Vermont | Verfahren und mittels zur manipulierung der expression des uncoupling proteins |
| GB9930100D0 (en) * | 1999-12-17 | 2000-02-09 | Smithkline Beecham Plc | New use |
| CA2534816A1 (en) | 2003-06-12 | 2004-12-23 | Evan Newell | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
| WO2005070126A2 (en) | 2004-01-08 | 2005-08-04 | The Regents Of The University Of Colorado | Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors |
| CA2602562C (en) | 2005-03-25 | 2015-07-07 | Alt Solutions, Inc. | Modulation of telomere length in telomerase positive cells and cancer therapy |
| CA2763671A1 (en) | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
| EP1877060A2 (en) * | 2005-04-28 | 2008-01-16 | The Regents of the University of Colorado | Therapeutic bifunctional compounds |
| US8329753B2 (en) * | 2005-05-02 | 2012-12-11 | The Regents Of The University Of Colorado | Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition |
| CN101588805A (zh) | 2005-05-18 | 2009-11-25 | Alt解决方案公司 | 为预防和治疗癌症对癌细胞中端粒长度的药理学调节 |
| US20070032383A1 (en) * | 2005-07-27 | 2007-02-08 | Newell M K | Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes |
| GB0610317D0 (en) * | 2006-05-24 | 2006-07-05 | Medical Res Council | Antiparasitic compounds and compositions |
| WO2009021034A2 (en) * | 2007-08-06 | 2009-02-12 | University Of Rochester | Methods of treating b-cell cancers |
| CA2716321A1 (en) * | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| WO2010008554A2 (en) | 2008-07-14 | 2010-01-21 | The Regents Of The University Of Colorado | Methods and products for treating proliferative diseases |
| WO2010051347A1 (en) * | 2008-10-31 | 2010-05-06 | David Sheikh-Hamad | A method for cardioprotection |
| US8450090B2 (en) | 2009-10-06 | 2013-05-28 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for promoting fatty acid production in plants |
| AU2010330823A1 (en) * | 2009-12-18 | 2012-07-05 | Joslin Diabetes Center, Inc. | Beta-cell replication promoting compounds and methods of their use |
| US9938279B2 (en) * | 2013-04-09 | 2018-04-10 | Energenesis Biomedical Co., Ltd | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935450A (en) | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| US4724234A (en) | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
| US5585363A (en) * | 1987-05-05 | 1996-12-17 | City Of Hope | Circumvention of human tumor drug resistance |
| US6113946A (en) | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| WO1994028897A2 (en) | 1993-06-07 | 1994-12-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection |
| CA2260766A1 (en) | 1996-07-12 | 1998-01-22 | Emory University | Regulation of apoptosis and in vitro model for studies thereof |
| AU2809797A (en) * | 1997-01-15 | 1998-08-07 | Centre National De La Recherche Scientifique Centre De Recherche Sur L'endocrinologie Moleculaire Et Le Developpement | Respiration uncoupling protein |
| AU6585498A (en) * | 1997-04-04 | 1998-10-30 | Amylin Pharmaceuticals, Inc. | Novel uncoupling protein and methods of use |
| AU7466198A (en) * | 1997-04-09 | 1998-10-30 | Beth Israel Deaconess Medical Center | Ucp3: an uncoupling protein homologue |
| EP1077724A2 (en) | 1998-04-17 | 2001-02-28 | The University Of Vermont | Methods and products related to metabolic interactions in disease |
| US7381413B1 (en) | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
| JP2002536009A (ja) | 1999-02-09 | 2002-10-29 | レキシコン・ジェネティクス・インコーポレーテッド | ヒト脱共役タンパク質およびそれをコードするポリヌクレオチド |
| ATE462447T1 (de) | 1999-06-23 | 2010-04-15 | Univ Vermont | Verfahren und mittels zur manipulierung der expression des uncoupling proteins |
| US7105718B2 (en) | 2000-03-31 | 2006-09-12 | The Regents Of The University Of Colorado | Compositions and methods for regulating metabolism in plants |
| JP2006512041A (ja) | 2001-10-12 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト | 活性酸素を用いる共刺激分子発現の調節のための方法 |
| US7341559B2 (en) * | 2002-09-14 | 2008-03-11 | Masimo Corporation | Pulse oximetry ear sensor |
-
2000
- 2000-06-22 AT AT00943076T patent/ATE462447T1/de not_active IP Right Cessation
- 2000-06-22 AU AU57600/00A patent/AU780815B2/en not_active Ceased
- 2000-06-22 CA CA002375508A patent/CA2375508A1/en not_active Abandoned
- 2000-06-22 WO PCT/US2000/017245 patent/WO2000078941A2/en not_active Ceased
- 2000-06-22 HK HK02106998.7A patent/HK1047032A1/zh unknown
- 2000-06-22 EP EP00943076A patent/EP1194168B1/en not_active Expired - Lifetime
- 2000-06-22 JP JP2001505684A patent/JP2003503319A/ja active Pending
- 2000-06-22 DE DE60044087T patent/DE60044087D1/de not_active Expired - Lifetime
-
2006
- 2006-04-21 US US11/409,446 patent/US7816319B2/en not_active Expired - Fee Related
-
2010
- 2010-10-19 US US12/907,434 patent/US20110206755A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003503319A5 (https=) | ||
| Cordova et al. | Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes | |
| Besancon et al. | Binding of interferon to gangliosides | |
| Ma et al. | Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response | |
| US5872104A (en) | Combinations and methods for reducing antimicrobial resistance | |
| US10966999B2 (en) | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | |
| JP6928083B2 (ja) | Ｐｄ−１ペプチド阻害剤 | |
| Singh et al. | Latency reversal 2.0: giving the immune system a seat at the table | |
| CN105377867A (zh) | I型干扰素的环状二核苷酸诱导 | |
| Hu et al. | A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model | |
| Harabuchi et al. | Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma | |
| Zhang et al. | Carcinogenic mechanisms of virus-associated lymphoma | |
| ES2272460T3 (es) | L-fmau para el tratamiento de la infeccion viral hepatitis delta. | |
| Meier et al. | C yclo Sal-BVDUMP Pronucleotides: How to Convert an Antiviral-Inactive Nucleoside Analogue into a Bioactive Compound against EBV | |
| Brignole et al. | Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities | |
| Missailidis et al. | Selection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting | |
| Ijaz et al. | From promise to progress: the dynamic landscape of glioblastoma immunotherapy | |
| Averett et al. | The pharmacology of endosomal TLR agonists in viral disease | |
| US7662792B2 (en) | Modulation of Fas and FasL expression | |
| Hayashi et al. | The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy | |
| Bashkin et al. | Ribozyme mimics as catalytic antisense reagents | |
| Diez-Torrubia et al. | Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs | |
| Benz et al. | Effects of adenine arabinoside on lymphocytes infected with Epstein-Barr virus | |
| Urata et al. | Anti-HIV-1 activity and mode of action of mirror image oligodeoxynucleotide analogue of Zintevir | |
| Sun et al. | Improved protease-targeting and biopharmaceutical properties of novel prodrugs of ganciclovir |